Recent research suggests that psilocybin, the active compound in “magic mushrooms,” may benefit cancer patients struggling with mental health issues when combined with therapy. The study, published in Nature Mental Health, indicates that this type of therapy can reduce anxiety, depression, and obsessive thoughts.
A cancer diagnosis often brings emotional turmoil. Patients face not only the physical challenges of the disease but also significant mental health impacts. Anxiety and depression are common, affecting between 35% and 65% of cancer patients. While traditional antidepressants are an option, they don’t always provide relief.
Dr. Petros D. Petridis, a psychiatrist at NYU Langone Health, emphasizes the need for new treatments. Many cancer patients struggle with deep psychological challenges, and existing medications might not be enough.
With growing interest in psychedelics as potential treatments, researchers are studying psilocybin’s effects through clinical trials. Petridis was particularly interested in how psilocybin-assisted therapy (PAP) could improve mental health for cancer patients.
In this study, researchers evaluated data from two previous trials involving 79 patients, most of whom had advanced cancer. Approximately half received a substantial dose of psilocybin, while others were given a lower dose or a placebo. Participants had therapy sessions before and after treatment doses, along with mental health assessments.
The results were promising. Those who received psilocybin therapy reported significant improvements in anxiety, depression, and other symptoms, effects lasting up to six months. Additionally, some physical symptoms linked to mental distress also improved.
Petridis remarked, “Our study showed that PAP could effectively help a wide range of mental health issues in cancer patients.” If validated by further research, it could enhance treatment options for this vulnerable group.
However, there are caveats. The study’s participants were primarily White and well-educated, which may limit how widely these findings can be applied. Additionally, the nature of psychedelic treatments may lead participants to guess their assigned group, potentially skewing the results.
While more extensive research is critical, initial findings are encouraging. PAP might be applicable to a broader range of mental health conditions beyond anxiety and depression.
Petridis hopes to broaden this research to include more diverse populations and explore psilocybin’s benefits in other areas of palliative care. With enough validation, he aims to integrate these therapies into standard mental health care.
Reference: Petridis PD, Grinband J, Agin-Liebes G, et al. Psilocybin-assisted psychotherapy improves psychiatric symptoms across multiple dimensions in patients with cancer. Nat Mental Health. 2024;2(11):1408-1414. doi: 10.1038/s44220-024-00331-0
About Dr. Petros D. Petridis: Dr. Petridis is a clinical assistant professor at the NYU Grossman School of Medicine, focusing on psilocybin’s potential to alleviate psychiatric distress in cancer patients and address alcohol use disorder. He earned his medical degree from Columbia University and completed his residency at NYU.
Check out this related article: Nutex Health Hospitals Achieve Community Excellence: Celebrating Awards Across 11 States!
Source link